FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20349

STATEMENT	OF CHANGES	S IN BENEFICIAL	<b>OWNERSHIP</b>

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	urden								
hours per response:	0.5								

1. Name and Address of Reporting Person*  Berelowitz Michael					2. Issuer Name <b>and</b> Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. ORMP										Check all ap	all applicable) Director		ng Person(s) to Issuer  10% Owner	
(Last) 415 EAS	`	(First) (Middle) H STREET				3. Date of Earliest Transaction (Month/Day/Year) 12/07/2015										Officer (give title below)		Other (specify below)	
(Street) NEW YO			10016 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Tab	le I - Nor	n-Deriv	vative	Se	curitie	s Acc	quired,	Dis	posed o	of, or	Bene	efici	ally Owr	ed			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		ar)	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispos Code (Instr. 5)		Dispose	rities Acquired (A ed Of (D) (Instr. 3,			and Secu Bene	nount of rities ficially ed Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	nt (A) or (D)		Pric	Tran	Transaction(s) (Instr. 3 and 4)			(111311.4)	
Common Stock			12/07/2015		5			S		539		D	\$8	3.7	24,357		D		
Common	Stock			12/0	8/201	5			S		761		D	\$8	3.7	7 23,596 D			
		Ta									sed of, onvertib				y Owne	i			
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security		n Date e (Month/Day/Year)	3A. Deemd Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)		of E		Expiratio	6. Date Exercisable and Expiration Date (Month/Day/Year)			le and unt of rities erlying rative rity (In:	str. 3	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ow For Dir or (I)	vnership rm: rect (D) Indirect (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	or	ount nber res					

**Explanation of Responses:** 

/s/ Michael Berelowitz

12/09/2015

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.